Related Experiment Video
Updated: Nov 15, 2025

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
Published on: August 4, 2023
The Novel Coronavirus and Haemostatic Abnormalities: Pathophysiology, Clinical Manifestations, and Treatment
S Louw1,2, B F Jacobson3,4, E S Mayne4,5
1Department of Molecular Medicine and Haematology, National Health Laboratory Service, Johannesburg, South Africa. Susan.louw@nls.ac.za.
Insights
The COVID-19 pandemic causes significant abnormal thrombosis, affecting both large and small blood vessels. Further research is needed to understand the virus
Area of Science:
- Virology
- Pathophysiology
- Hematology
Background:
- The COVID-19 pandemic, caused by SARS-CoV-2, shares similarities with the previous SARS epidemic due to their shared coronavirus origin.
- A key differentiator of COVID-19 is the significant morbidity and mortality associated with abnormal thrombosis.
- This thrombotic phenomenon impacts both macrovascular and microvascular levels, presenting uniquely in this disease.
Purpose of the Study:
- To highlight the unique thrombotic complications of COVID-19.
- To discuss the presence of SARS-CoV-2 in pulmonary endothelium and its link to respiratory issues.
- To address the elevated D-dimer levels observed in COVID-19 patients.
Main Methods:
- Review of existing literature on COVID-19 pathophysiology.
- Analysis of clinical observations regarding thrombosis in COVID-19.
- Examination of viral presence in affected tissues.
Main Results:
- COVID-19 is characterized by unique macro- and microvascular thrombosis.
- SARS-CoV-2 has been identified in the endothelium of pulmonary alveoli, contributing to respiratory distress.
- Elevated D-dimer concentrations are a frequent finding in COVID-19 patients.
Conclusions:
- Abnormal thrombosis is a major contributor to COVID-19 severity.
- The precise pathophysiological mechanisms of COVID-19 require further elucidation.
- Optimal anticoagulation strategies for COVID-19 are yet to be established.
Abstract:
The COVID-19 pandemic, caused by the SARS-C0V-2 virus, was initially considered and managed in a similar manner to the previous SARS epidemic as they are both caused by coronaviruses. What has now become apparent is that a major cause of morbidity and mortality in COVID-19 is abnormal thrombosis. This thrombosis occurs on a macro- and microvascular level and is unique to this disease. The virus has been demonstrated in the endothelium of the pulmonary alveoli and as such is thought to contribute to the devastating respiratory complications encountered. D-dimer concentrations are frequently raised in COVID to levels not frequently seen previously. The optimal anticoagulation treatment in COVID remains to be determined, and the myriad of pathophysiologic effects caused by this virus in the human host have also yet to be fully elucidated.
Related Concept Videos
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Introduction to Hemostasis
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
Venous Thrombosis III: Interprofessional Care
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
Venous Thrombosis IV: Nursing Management

